ACHIEVEMENTS

PUBLICATION

2024

  • Sugata K, Takatori M, Reda O, Tan BJY, Tokunaga M, Sato T, Ueda M, Yamano Y, Utsunomiya A, Satou Y. Viral antigen mismatch affects antiviral T-cell response and may impair immunotherapeutic efficacy against adult T-cell leukemia/lymphoma. The Journal of Infectious Diseases. 2024, jiae457. doi:10.1093/infdis/jiae457
  • White E, Papagno L, Samri A, Sugata K, Hejblum B, Henry AR, Rogan DC, Darko S, Recordon-Pinson P, Dudoit Y, Llewellyn-Lacey S, Chakrabarti LA, Buseyne F, Migueles SA, Price DA, Andreola MA, Satou Y, Thiebaut R, Katlama C, Autran B, Douek DC, Appay V. Clonal succession after prolonged antiretroviral therapy rejuvenates CD8+ T cell responses against HIV-1. Nature Immunology. 25(9):1555-1564. doi: 10.1038/s41590-024-01931-9.
  • Nyame P, Togami A, Yoshida T, Masunaga T, Begum MM, Terasawa H, Monde N, Tahara Y, Tanaka R, Tanaka Y, Appiah-Kubi J, Amesimeku WO, Hossain MJ, Otsuka M, Yoshimura K, Ikeda T, Sawa T, Satou Y, Fujita M, Maeda Y, Tateishi H, Monde K. A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24. J Biol Chem. Online ahead of print. 107701. doi: 10.1016/j.jbc.2024.107701.
  • Hossain B, Uchiyama Y, Rajib SA, Rahman A, Takatori M, Tan BJY, Sugata K, Nagashima M, Kawakami M, Ito H, Kumagai R, Sadamasu K, Ogi Y, Kawaguchi T, Tamura T, Fukuhara T, Ono M, Yoshimura K, Satou Y. A micro-disc-based multiplex method for monitoring emerging SARS-CoV-2 variants using the molecular diagnostic tool Intelli-OVI. Communications medicine. 2024, 4(161), doi: 10.1038/s43856-024-00582-z
  • Begum MM, Bokani A, Rajib SA, Soleimanpour M, Maeda Y, Yoshimura K, Satou Y, Ebrahimi D, Ikeda T. Potential Role of APOBEC3 Family Proteins in SARS-CoV-2 Replication. Viruses. 16(7):1141. doi: 10.3390/v16071141.
  • Omnia R, Monde K, Sugata K, Rahman A, Sakhor W, Rajib SA, Sithi SN, Tan BJY, Niimura K, Motozono C, Maeda K, Ono M, Takeuchi H, Satou Y. HIV-Tocky system to visualize proviral expression dynamics. Communications Biology, 7: 344, 2024. doi: 10.1038/s42003-024-06025-8.
  • Ono M and Satou Y. Spectrum of Treg and Self-Reactive T cells: Single Cell Perspectives from Old Friend HTLV-1. Discovery Immunology 3(1):kyae006, 2024  doi: 10.1093/discim/kyae006.
  • Miyamura Y, Kamei S, Matsuo M, Usuki S, Uemura A, Satou Y, Ohguchi H, and Minami T.FOXO1 stimulates tip cell-enriched gene expression in endothelial cells. iScience, 2024, 27(3), 109161. doi: 10.1016/j.isci.2024.109161.
  • Konno Y, Uriu K, Chikata T, Takada T, Kurita JI, Ueda MT, Islam S, Yang Tan BJ, Ito J, Aso H, Kumata R, Williamson C, Iwami S, Takiguchi M, Nishimura Y, Morita E, Satou Y, Nakagawa S, Koyanagi Y, Sato K.Two-step evolution of HIV-1 budding system leading to pandemic in the human population. Cell Rep. 2024, 43(2),113697,doi: 10.1016/j.celrep.2024.113697

2023

  • Tomita Y, Sakata S, Imamura K, Iyama S, Jodai T, Saruwatari K, Hamada S, Akaike K, Anai M, Fukusima K, Takaki A, Tsukamoto H, Goto Y, Motozono C, Sugata K, Satou Y, Ueno T, Ikeda T, Sakagami T. Association of Clostridium butyricum therapy using the live bacterial product CBM588 with the survival of patients with lung cancer receiving chemoimmunotherapy combination. Cancer. 2023, 16(1), 47, doi: 10.3390/cancers16010047.
  • Nakahata S, Enriquez-Vera D, M. Jahan I, Sugata K, Satou Y. Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review.Biomolecules, 2023, 13(10), 1543, doi: 10.3390/biom13101543.
  • Matsuda K, Tan BJY, Tsuchiya K, Rajib SA, Satou Y and Maeda K.Assessing the effects of antiretroviral therapy-latency-reversing agent combination therapy on eradicating replication-competent HIV provirus in a Jurkat cell culture model. STAR Protocol. 2023, 4(4), 102547,doi: 10.1016/j.xpro.2023.102547.
  • Katsuya H, Nakamura H, Maeda A, Ishii K, Nagaie T, Sano H, Sano H, Itamura H, Okamoto S, Ando T, Watanabe T, Uchimaru K, Satou Y, Sueoka E, Kimura S. HTLV-1 cell-free DNA in plasma as a potential biomarker in HTLV-1 carriers and adult T-cell leukemia-lymphoma. eJHaem. 2023, 4(3), 733-737, doi: 10.1002/jha2.725.
  • Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BJY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, Wei F, Fu L, Zhang J, Kitamura F, Yamashita K, Eto K, Iwagami S, Tsukamoto H, Umemoto T, Masuda M, Nagano O, Satou Y, Saya H, Tan P, Baba H, Ishimoto T. Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors. CANCER RESEARCH. 83 (5), 753–770, 10.1158/0008-5472.CAN-22-1890
  • Hossain B, Kobayashi T, Makimoto S, Matsuo M, Nishikaku K, Tan B, Rahman A, Rajib SA, Sugata K, Ohnuki N, Saito M, Inenaga T, Imakawa K, Satou Y. Clone Dynamics and Its Application for the Diagnosis of Enzootic Bovine Leukosis. Journal of Virology. doi:https://doi.org/10.1128/jvi.01542-22

2022

  • Tan B, Sugata K, Ono M and Satou Y. HTLV-1 persistence and leukemogenesis: A game of hide-and-seek with the host immune system. Frontiers in Immunology. 13:991928. doi: 10.3389/fimmu.2022.991928
  • Tan B, Ono M, Satou Y. Single-cell transcriptome analysis of Treg, In: Ono M. (eds) Regulatory T Cells. pp259-278.
  • Maksimova V, Smith S, Seth J, Phelps C, Niewiesk S, Satou Y, Green P, Panfil A. Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Frontiers in Immunology. 13:954077. doi: 10.3389/fimmu.2022.954077
  • Matsuo M, Ueno T, Monde K, Sugata K, Tan B, Rahman A, Miyazato P, Uchiyama K, Islam S, Katsuya H, Nakajima S, Tokunaga M, Nosaka K, Hata H, Utsunomiya A, Fujisawa,  Satou Y. Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nature Communications. 13,2405, 2022. doi:10.1038/s41467-022-30029-9
  • Monde K, Satou Y, Goto M, Uchiyama Y, Ito J, Kaitsuka T, Terasawa H, Monde N, Yamaga S, Matsusako T, Wei FY, Inoue I, Tomizawa K, Ono A, Era T, Sawa T, Maeda Y. Movements of Ancient Human Endogenous Retroviruses Detected in SOX2-Expressing Cells., J Virol. in press
  • Rajib SA, Ogi Y, Hossain MB, Tanaka E, Kawaguchi T, Satou Y. A SARS-CoV-2 Delta variant containing mutation in the probe binding region used for qRT-PCR test in Japan exhibited atypical PCR amplification and might induce false negative result Journal of Infection and Chemotherapy in press
  • Katsuya H, Cook L, Rowan AG, Melamed A, Turpin J, Ito J, Islam S, Miyazato P, Tan B, Matsuo M, Miyakawa T, Nakata H, Matsushita S, Taylor GP, Bangham CRM, Kimura S, Satou Y. Clonality of HIV-1 and HTLV-1 infected cells in naturally coinfected individuals. The Journal of Infectious Diseases 225(2), 317-326, 2022.

2021

  • Tan B, Sugata K, Reda O, Matsuo M, Uchiyama K, Miyazato P, Hahaut V, Yamagishi M, Uchimaru K, Suzuki Y, Ueno T, Suzushima H, Katsuya H, Tokunaga M, Uchiyama Y, Nakamura H, Sueoka E, Utsunomiya A, Ono M, Satou Y. HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. The Journal of Clinical Investigation 131(24), e150472, 2021.
  • Matsuda K, Islam S, Takada T, Tsuchiya K, Tan B, Hattori S, Katsuya H, Kitagawa K, Kim K,Matsuo M, Sugata K, Delino N, Gatanaga H, Yoshimura K, Matsushita S, Mitsuya H, Iwami S, Satou Y, Maeda K. A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. Cell Reports Methods 1(8), 100122, 2021.
  • Hiyoshi M, Takahashi N, Eltalkhawy YM, Noyori O, Lotfi S, Panaampon J, Okada S, Tanaka Y, Ueno T, Fujisawa JI, Sato Y, Suzuki T, Hasegawa H, Tokunaga M, Satou Y, Yasunaga JI, Matsuoka M, Utsunomiya A, Suzu S. M-Sec induced by HTLV-1 mediates an efficient viral transmission. PLoS Pathogens 17:e1010126, 2021.
  • Ohnuki N, Kobayashi T, Matsuo M, Nishikaku K, Kusama K, Torii Y, Inagaki Y, Hori M, Imakawa K, Satou Y. A target enrichment high throughput sequencing system for characterization of BLV whole genome sequence, integration sites, clonality and host SNP. Scientific Reports 11(1), 4521, 2021.
  • Sugata K,Matsunaga Y, Yamashita Y, Nakatsugawa M, Guo T, Halabelian L, Ohashi Y, Saso K, Rahman M, Anczurowski M, Wang C, Murata K, Saijo H, Kagoya Y, Ly D, Burt B, Butler M, Mak T, Hirano N. Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Nature Biotechnology doi: 10.1038/s41587-021-00836-4, 2021.

2020

2019

  • Miyazato P, Matsuo M, Tan BJY, Tokunaga M, Katsuya H, Islam S, Ito J, Murakawa Y, Satou Y. HTLV-1 contains a high CG dinucleotide content and is susceptible to the host antiviral protein ZAP. Retrovirology, 16(1):38, doi: 10.1186/s12977-019-0500-3,2019.
  • Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, Inada Y, Iwase SC, Uchiyama Y, Hata H, Sato T, Yagishita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagishi M, Watanabe T, Uchimaru K, Fujisawa JI, Utsunomiya A, Yamano Y, Satou Y. The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach. Cell Reports, 29(3):724-735.e4, doi: 10.1016/j.celrep.2019.09.016, 2019.
  • Iwase S, Miyazato P, Katsuya H, Islam S, Tan BJY, Ito J, Matsuo M, Takeuchi H, Ishida T, Matsuda K, Maeda K and Satou Y. HIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus.
    Scientific Reports, 29(3):724-735.e4, doi: 10.1016/j.celrep.2019.09.016, 2019.
  • Baba M, Furuya M, Motoshima T, Martin L, Funasaki S, Wenjuan M, Hong-Wei S, Hasumi H, Ying H, Kato I,
    Kadomatsu T, Satou Y, Nicole MN, Baktiar OK, Lilia I, Joseph DK, Luh AWK, Hasumi Y, Sugiyama A,
    Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T,
    Oike Y, Laura SS and W. Marston L. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease.
    Molecular Cancer Research, 17(8):1613-1626, doi: 10.1158/1541-7786.MCR-18-1235, 2019.
  • 松尾美沙希、宮里パオラ、佐藤賢文
    「HTLV-1感染細胞クローン選択におけるウイルス組み込み部位の意義
    〜レトロウイルスHTLV-1とヒトゲノムの相互作用に関する最近の話題〜」     ウイルス　第69巻 第1号　2019年
  • 佐藤賢文「HIV-1ウイルスリザーバの成立・維持の仕組み」 日本エイズ学会誌　21:167-172　2019年

2018

  • Miura M, Miyazato P, Satou Y, Tanaka Y, Bangham CRM. Spontaneous HTLV-1 transcription is accompanied by distinct epigenetic changes in the 5′ and 3′ long terminal repeats.
    Wellcome Open Research, 3:105, doi: 10.12688/wellcomeopenres.14741.2. eCollection 2018, 2018.
  • Katsuya H, Cook LBM, Rowan AG, Satou Y, Taylor GP, Bangham CRM. Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma.
    Biomarker Research, 6:24, doi: 10.1186/s40364-018-0138-7, 2018.
  • Stanoeva K, Konig A, Fukuda A, Kawanami Y, Kuwata T,
    Satou Y, Matsushita S. Total HIV-1 DNA dynamics and influencing factors in long-term ART-treated Japanese adults: retrospective longitudinal analysis.
    Journal of Acquired Immune Deficiency Syndromes, 78(2):239-247, doi: 10.1097/QAI.0000000000001662, 2018.

2017

  • Satou Y, Katsuya H, Fukuda A, Misawa N, Ito J, Uchiyama Y,
    Miyazato P,
    Islam S, Fassati A, Melamed A, Bangham CRM, Koyanagi Y, Sato K. Dynamics and mechanisms of clonal expansion of HIV-1-infected cells in a humanized mouse model.
    Scientific Reports, 7(1):6913, doi: 10.1038/s41598-017-07307-4, 2017.

2016

  • Miyazato P, Katsuya H,
    Fukuda A, Uchiyama Y, Matsuo M, Tokunaga M, Hino S , Nakao M, Satou Y. Application of targeted enrichment to next-generation sequencing of retroviruses integrated into the host human genome. Scientific Reports, 6:28324, doi: 10.1038/srep28324, 2016.
  • Miyazato P, Matsuo M, Katsuya H, Satou Y. Transcriptional and Epigenetic Regulatory Mechanisms affecting HTLV-1 provirus. Viruses, 8(6):171, doi: 10.3390/v8060171, 2016.
  • Satou Y, Miyazato P, Ishihara K, Yaguchi H, Melamed A, Miura M,
    Fukuda A, Nosaka K, Watanabe T, Rowan A, Nakao M, Bangham C. The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome. Proceedings of the National Academy of Sciences of the United States of America, 113(11):3054-9, doi: 10.1073/pnas.1423199113, 2016.
    [熊大HP][EurekAlert!HP][HTLV-1学会]

2014

  • Zhao T, Satou Y, Matsuoka M. Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice. Archives of Virology. 159(7):1849-56, doi: 10.1007/s00705-014-2099-y, 2014.

2013

  • Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, Dong Sung An and Koyanagi Y. HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLoS Pathogens, 9(12):e1003812, doi: 10.1371/journal.ppat.1003812, 2013.
  • Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog., 9(9):e1003630, doi: 10.1371/journal.ppat.1003630, 2013.
  • Satou Y, Matsuoka M. Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1.Reviews in Medical Virology, 10:885, doi: 10.3389/fmicb.2019.00885, 2013.

2012

  • Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M. HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals. Retrovirology, 9:46, doi: 10.1186/1742-4690-9-46, 2012.
  • Sugata K, Satou Y, Yasunaga J, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, and Matsuoka M. HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines, Blood, 119(2):434-44, doi: 10.1182/blood-2011-05-357459, 2012.
  • Satou Y, Matsuoka M. Molecular and cellular mechanism of leukemogenesis of ATL; emergent evidence of significant role of HBZ in HTLV-1-induced pathogenesis. Leukemia Research and Treatment, 2012:213653, doi: 10.1155/2012/213653, 2012.

2011

  • Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, and Matsuoka M. HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator. Blood, 118: 118(7):1865-76, doi: 10.1182/blood-2010-12-326199, 2011.
  • Shimizu-Kohno K, Satou Y, Arakawa F, Kiyasu J, Kimura Y, Niino D, Sugita Y, Ishikawa F, Matsuoka M, Ohshima K. Detection of human T-cell leukemia virus type 1 by means of HBZ in situ hybridization in formalin-fixed and paraffin-embedded tissues. Cancer Science, 102(7):1432-6, doi: 10.1111/j.1349-7006.2011.01946.x, 2011.
  • Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, Matsuoka M, Takahashi R, Kuzushima K, Ito M, Takada K, and Koyanagi Y. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood, 117(21):5663-73, doi: 10.1182/blood-2010-09-305979, 2011.
  • Hagiya K, Yasunaga J, Satou Y, Oshima K and Matsuoka M. ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology, 8:19, doi: 10.1186/1742-4690-8-19, 2011.
  • Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, Shimizu K, Ohshima K, Green P, Ohkura N, Yamaguchi T, Ono M, Sakaguchi S, Matsuoka M, HTLV-1 bZIP Factor Induces T-cell Lymphoma and Systemic Inflammation In Vivo.PLoS Pathogens, 7(2):e1001274, doi: 10.1371/journal.ppat.1001274, 2011.

~2010

  • Satou Y and Matsuoka M. HTLV-1 and the host immune system: How the virus disrupts immune regulation, leading to HTLV-1 associated diseases. Journal of Clinical and Experimental Hematopathology, 50(1):1-8, doi: 10.3960/jslrt.50.1, 2010.
  • Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, Matsuoka M. APOBEC3G Generates Nonsense Mutations in HTLV-1 Proviral Genomes In Vivo. Journal of Virology, 84(14):7278-87, doi: 10.1128/JVI.02239-09, 2010.
  • Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, Matsuoka M, Ohara Y. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology, 6:19, doi: 10.1186/1742-4690-6-19, 2009.
  • Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M. Human T-cell Leukemia virus type 1 bZIP factor selectively suppresses classical pathway of NF-kB. Blood, 113(12):2755-64, doi: 10.1182/blood-2008-06-161729, 2009.
  • Yoshida M, Satou Y, Yasunaga JI, Fujisawa JI, Matsuoka M. Transcriptional control of spliced and unspliced HTLV-1 bZIP factor gene. Journal of Virology, 86(2):107-12, doi: 10.1532/IJH97.07103, 2008.
  • Satou Y, Matsuoka M. Implication of the HTLV-I bZIP Factor Gene in the Leukemogenesis of Adult T-Cell Leukemia. International Journal of hematology, 107-12, doi: 10.1532/IJH97.07103, 2007.
  • Satou Y, Yasunaga JI, Yoshida M, Matsuoka M. HTLV- I bZIP factor gene mRNA supports proliferation of adult T-cell leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 113(12):2755-64, doi: 10.1182/blood-2008-06-161729, 2006.
  • Doi K, Wu X, Taniguchi Y, Yasunaga JI, Satou Y, Okayama A, Nosaka K, Matsuoka M. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood, 106(3):1048-5, doi: 10.1182/blood-2004-11-4350, 2005.
  • Yasunaga JI, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Research, 64(17):6002-9, doi: 10.1158/0008-5472.CAN-04-1422, 2004.
  • Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia, 18(8):1357-63, doi: 10.1038/sj.leu.2403400, 2004.